| European Case Law Identifier: | ECLI:EP:BA:2013:T073412.20130517 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 17 May 2013 | ||||||||
| Case number: | T 0734/12 | ||||||||
| Application number: | 04759142.5 | ||||||||
| IPC class: | A61K 39/395 C07K 16/28 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor | ||||||||
| Applicant name: | Genentech, Inc. | ||||||||
| Opponent name: | Teva Pharmaceutical Industries LTD. Stada R & D GmbH Sandoz AG |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Added matter, extension of protection (no) Clarity, sufficiency of disclosure, novelty (yes) Inventive step (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t120734eu1.html
Date retrieved: 17 May 2021